{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:59:19Z","timestamp":1790330359256,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003227"],"award-info":[{"award-number":["82003227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Evidence Based Medicine"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Several first\u2010line immunotherapy\u2010based regimens are available for patients with programmed death ligand 1 positive advanced or metastatic triple\u2010negative breast cancer, but their relative economic value in China remains uncertain. This study evaluated selected regimens from the perspective of the Chinese healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed an exploratory cross\u2010trial partitioned survival model using survival data from the IMpassion130, KEYNOTE\u2010355, TORCHLIGHT, and ASCENT\u201004 Phase III trials, with utility and cost inputs from published sources and the Chinese healthcare setting. Outcomes included total costs, life\u2010years (LYs), quality\u2010adjusted life\u2010years (QALYs), and incremental cost\u2010utility ratios. Pairwise comparisons used a willingness\u2010to\u2010pay threshold of USD 43,333 per QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pembrolizumab plus Sacituzumab Govitecan yielded the most LYs and QALYs, but at the highest cost. Toripalimab plus chemotherapy had the lowest cost, produced health outcomes similar to those of Pembrolizumab plus chemotherapy, and had the most favorable economic profile at the prespecified threshold. Pembrolizumab plus chemotherapy was cost\u2010effective versus Atezolizumab plus chemotherapy. Pembrolizumab plus Sacituzumab Govitecan was not cost\u2010effective, as its limited incremental benefit did not offset its substantially higher cost. Sensitivity analyses generally supported the base\u2010case findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among the regimens evaluated, Toripalimab plus chemotherapy provided the most favorable balance between costs and health outcomes in China. Pembrolizumab plus chemotherapy also offered reasonable economic value versus Atezolizumab plus chemotherapy, whereas the value of Pembrolizumab plus Sacituzumab Govitecan was constrained by its high acquisition cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jebm.70184","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:49:50Z","timestamp":1787039390000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Cost\u2010Effectiveness of First\u2010Line Immunotherapy\u2010Based Regimens for Advanced Triple\u2010Negative Breast Cancer"],"prefix":"10.1111","volume":"19","author":[{"given":"Xiaoyue","family":"Sun","sequence":"first","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fandi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Head and Neck Tumor Multimodality Treatment Cancer Center West China School of Medicine and West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"},{"name":"Division of Head and Neck Tumor Multimodality Treatment Cancer Center West China School of Medicine and West China Hospital Sichuan University  Chengdu China"},{"name":"Department of Radiation Oncology Cancer Center West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"},{"name":"Division of Head and Neck Tumor Multimodality Treatment Cancer Center West China School of Medicine and West China Hospital Sichuan University  Chengdu China"},{"name":"Department of Radiation Oncology Cancer Center West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jing","sequence":"additional","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Luo","sequence":"additional","affiliation":[{"name":"Nephrology Department Yan'an Hospital of Kunming City Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Head and Neck Tumor Multimodality Treatment Cancer Center West China School of Medicine and West China Hospital Sichuan University  Chengdu China"},{"name":"Department of Radiation Oncology Cancer Center West China Hospital Sichuan University Chengdu China"},{"name":"Laboratory of Liquid Biopsy and Single Cell Research West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lan","sequence":"additional","affiliation":[{"name":"Institute of Breast Health Medicine State Key Laboratory of Biotherapy West China Hospital Sichuan University and Collaborative Innovation Center  Chengdu China"},{"name":"Tianfu Jincheng Laboratory  Chengdu China"},{"name":"Division of Head and Neck Tumor Multimodality Treatment Cancer Center West China School of Medicine and West China Hospital Sichuan University  Chengdu China"},{"name":"Department of Radiation Oncology Cancer Center West China Hospital Sichuan University Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01121-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00468-0"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.576964"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314937"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02677-x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508959"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0036"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920916000"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0082"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-025-01445-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1654177"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454579"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"e_1_2_7_18_1","volume-title":"China Guidelines for Pharmacoeconomic Evaluations 2020","author":"Liu G. G.","year":"2020"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab108"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01724-2"},{"key":"e_1_2_7_21_1","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta\u2010Analysis of Randomised Controlled Trials","author":"Dias S.","year":"2014"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12455847"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X221097081"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9810"},{"key":"e_1_2_7_25_1","unstructured":"A.Rohatgi \u201cWebPlotDigitizer \u201d cited 2026 Jul 24 https:\/\/automeris.io."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000671"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1421826"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61097-1"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00613-z"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02516-9"},{"key":"e_1_2_7_33_1","unstructured":"National Healthcare Security Administration \u201cList of Medicines With Changes in Reimbursement Scope in the 2025 National Reimbursement Drug List (65 Medicines) \u201d cited 2026 Jul 24 https:\/\/www.nhsa.gov.cn\/module\/download\/downfile.jsp?classid=0&filename=5ac105c32b2145d9add107c52249da6b.pdf."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.02.003"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01069-8"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"}],"container-title":["Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jebm.70184","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jebm.70184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:02:22Z","timestamp":1790326942000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jebm.70184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jebm.70184"],"URL":"https:\/\/doi.org\/10.1111\/jebm.70184","archive":["Portico"],"relation":{},"ISSN":["1756-5383","1756-5391"],"issn-type":[{"value":"1756-5383","type":"print"},{"value":"1756-5391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"2026-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70184"}}